TET2 and heart failure: Consistently, findings from both studies have shown that the treatment with MCC950, a specific NLRP3 inflammasome inhibitor, was able abrogate the exacerbated IL-1B secretion, promoting an atheroprotective effect and hindering the development of heart failure in these murine models for clonal hematopoiesis associated with TET2 somatic mutations (97, 98).